Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT00003903 Completed - Prostate Cancer Clinical Trials

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

Start date: July 1999
Phase: N/A
Study type: Interventional

RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more comfortably. PURPOSE: Clinical trial to determine the effect of androgen suppression on bone loss in patients who have prostate cancer.

NCT ID: NCT00003871 Completed - Prostate Cancer Clinical Trials

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Start date: September 24, 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of PSA vaccines in treating patients who have advanced prostate cancer.

NCT ID: NCT00003832 Completed - Clinical trials for Stage I Prostate Cancer

Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer

Start date: July 1999
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment

NCT ID: NCT00003819 Completed - Prostate Cancer Clinical Trials

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Start date: June 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.

NCT ID: NCT00003781 Completed - Prostate Cancer Clinical Trials

Docetaxel in Treating Patients With Stage IV Prostate Cancer

Start date: December 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial of docetaxel in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.

NCT ID: NCT00003740 Completed - Prostate Cancer Clinical Trials

Trastuzumab in Treating Patients With Prostate Cancer

Start date: October 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have prostate cancer that has not responded to hormone therapy.

NCT ID: NCT00003690 Completed - Breast Cancer Clinical Trials

Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors

Start date: December 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of flavopiridol plus cisplatin or carboplatin in treating patients who have advanced solid tumors.

NCT ID: NCT00003674 Completed - Breast Cancer Clinical Trials

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Start date: December 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients with advanced cancer that has not responded to previous treatment. It is not yet known if standard therapy is more effective with or without dalteparin in treating advanced breast, lung, colorectal, and prostate cancer. PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of standard therapy with or without dalteparin in treating patients who have advanced breast, lung, colorectal, or prostate cancer that has not responded to previous chemotherapy or hormone therapy.

NCT ID: NCT00003653 Completed - Prostate Cancer Clinical Trials

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Start date: January 5, 1999
Phase: Phase 3
Study type: Interventional

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. It is not yet known which androgen suppression regimen is more effective for prostate cancer. PURPOSE: This randomized phase III trial is studying two hormone therapy regimens and comparing them to see how well they work in treating patients with rising PSA levels following radiation therapy for prostate cancer.

NCT ID: NCT00003626 Completed - Prostate Cancer Clinical Trials

Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Start date: October 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic prostate cancer that has not responded to previous hormone therapy.